HOME >> MEDICINE >> NEWS
Predictors of undergoing joint replacement surgery among patients with severe osteoarthritis

A progressive, destructive joint disease, osteoarthritis (OA) is a major cause of disability worldwide. Total joint arthroplasty (TJA) is a highly successful and cost-effective procedure for managing OA of the hip and knee. Despite this, analyses of hospital records show variations in the rates of TJA by region, gender, race, and socioeconomic status. While these studies tell us about who is undergoing hip and knee replacement surgery, what's missing is why--a comprehensive, rigorous examination of the predisposing factors affecting TJA rates.

Why do some arthritis sufferers agree to undergo TJA and others resist it? To examine the predictors of time to a first TJA, a team of Canadian researchers, affiliated with the University of Toronto and other research institutes, conducted a population-based study of 2,128 individuals ages 55 and over with disabling OA of the hip and/or knee. Their findings, featured in the October 2006 issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis), support the need for community-based education about arthritis treatments, including hip and knee replacement surgery.

This groundbreaking study focused on two regions of Ontario--one rural with high rates of TJA and one urban with low rates. It started in 1999 with an established sample of older citizens--1,158 from the country; 970 from the city--with severe hip and/or knee OA and no prior joint replacement. Researchers devoted 7 years to follow up, consisting of annual surveys and check-ups on disease progression, linked with hospital databases to determine whether patients had undergone hip or knee replacement surgery.

Among the study population, 73 percent were women, 96 percent were white, 31 percent were living alone, independently, and nearly 68 percent had a high school education or higher. At baseline,
'"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
28-Sep-2006


Page: 1 2 3

Related medicine news :

1. Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
2. Should patients undergoing surgery get ASA?
3. Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
4. Women with endometriosis undergoing IVF benefit from treatment with GnRH agonists
5. Distant prayer does not improve clinical outcome for patients undergoing coronary procedures
6. Patients may want to skip that cup of coffee before undergoing PET/CT scans
7. New methods offer alternatives for patients undergoing obesity surgery
8. Vicente Fox Center and RAND launch joint program to find policies to combat poverty
9. Experimental gene therapy abolishes arthritis pain and lessens joint damage
10. Slick and springy: Brown research reveals proteins role in joints
11. Key study offers hope to patients with lung and joint disease

Post Your Comments:
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... Designers and Professionals of FCPX ... 5K from Pixel Film Studios. , “Scratches 5K allows ... inside Final Cut Pro X” Said Christina Austin, CEO ... is an effective tool for any FCPX editor.” , ... intuitive grunge overlays. Simply drag title layers into the ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Wellness for ... and business criteria for the spa and wellness industry–has ... clients who have experienced or are living with cancer. ... Spafinder Wellness 365® Network, will be identified with a ... as a provider of safe, therapeutic services for cancer ...
(Date:3/27/2015)... York (PRWEB) March 27, 2015 The ... ) that allege the statin medication increases the risk ... granted Pfizer Inc.’s Motion to Dismiss four individual cases ... a Case Management Order issued in the U.S. District ... Court determined that the dismissals were warranted because the ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
(Date:3/27/2015)... March 27, 2015 As of February, ... incontinence devices for women. "Shipping thousands ... gratifying part is the hundreds of letters, emails ... lives have been positively impacted by our technology," ... InControl recently released Apex, an over-the-counter ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
Cached News: